Celator(R) Pharmaceuticals To Present at Biotech Sho... ( PRINCETON N.J. Jan. 8 /- Celator Phar...)

Celator(R) Pharmaceuticals To Present at Biotech Showcase 2009

Date:1/8/2009

PRINCETON, N.J., Jan. 8 /PRNewswire/ -- Celator Pharmaceuticals today announced that Scott Jackson, chief executive officer, is scheduled to present at the Biotech Showcase 2009 in San Francisco. Mr. Jackson will provide a corporate overview and an update on the company's clinical development programs. The presentation will be held on Wednesday, January 14, 2009 at 10:30AM PST in Room A of the Marines' Memorial Club & Hotel.

About Celator

Celator(R) Pharmaceuticals, Inc., with locations in Princeton, NJ, and Vancouver, BC, is a privately held pharmaceutical company developing new and more effective therapies to treat cancer. CombiPlex(R), the company's drug ratio technology platform, represents a novel approach that identifies molar ratios of drugs that will deliver a synergistic benefit, locks the desired ratio in a drug delivery vehicle that maintains the ratio in patients with the goal of improving clinical outcomes. The company pipeline includes: CPX-1 (a liposomal formulation of irinotecan:floxuridine), currently in Phase 2 in patients with colorectal cancer; CPX-351 (a liposomal formulation of cytarabine:daunorubicin), currently in Phase 2 in patients with acute myeloid leukemia; CPX-571 (a liposomal formulation of irinotecan:cisplatin), a preclinical stage compound; and multiple research programs. Based on the applications of CombiPlex, Celator is positioned to advance a broad pipeline of combination therapies involving both previously approved and novel drug agents. For more information, please visit the company's website at www.celatorpharma.com.

SOURCE Celator Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Post Your Comments:

(Date:12/5/2009)... , NEW ORLEANS, Dec. 5 /PRNewswire-USNewswire/ ...erious and often deadly blood cancers. Research pr...erican Society of Hematology introduces potential ...ods for patients suffering from acute promyelocyti... lymphoblastic leukemia, and myelofibrosis that ar...

(Date:12/5/2009)... AVIVA today announced the launch of...ational private medical insurance plan which follo...nt. In addition to offering customers the flexibil...it their needs and budgets, International Solution...mplement those already offered in their country of...

(Date:12/4/2009)...NEW YORK, Dec. 4 Care I...e "Company") today announced that its Board of Dir...of common stock. The dividend is payable on Decem...ecember 14, 2009. ,, About Care Investment ...estate investment and finance company investing in...

(Date:12/4/2009)...WASHINGTON, Dec. 4 The ... Aging (AAHSA) applauds the Senate for ensuring th...CLASS) provisions remain in the final health refor... for providing support to elders, people with disa...Senate to pass a health care reform bill that will...

(Date:12/4/2009)..., ANAHEIM, Calif., Dec. 4 Pamela ...hcare, was selected as a finalist for the "Chief I...scent,s business with the power of cloud computing...ir innovative usage of Salesforce CRM or the Force...uccess to their sales, marketing, partner, service...

[0] Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders [0] AVIVA's Private Health Insurance Products Solutions Go International [0] Care Investment Trust Inc. Declares Quarterly Dividend of $0.17 Per Share [0] Statement from AAHSA CEO Larry Minnix on the Failure of the Thune Amendment [0] Crescent CIO '09 Dreamforce Conference Speaker and Award Finalist

... Colorado Court of Appeals handed,State Farm Mutua...ng a,trial-court ruling supporting the insurance g...mbursements of medical costs. The ruling, issued ...unilaterally reduced after the insurance,company p...

...rogen Pharmaceuticals,Limited (ASX: PGL; Nasdaq: P...-cancer drug PI-88 has been awarded Fast Track sta.... The fast track designation has been granted,to P... Under the FDA Modernization Act of 1997, the fas...

... Benjamin England,Special Counsel with Jones Walke...ture, Rural Development, Food and Drug Administrat...on Appropriations, on Tuesday, September,25, 2007 ...ategic Plan that relates to the import of food, dr...

...24 While most patients and physicians believe its...xam, theres growing debate about this conventional...ue of the Archives of Internal Medicine raises ser... the number, cost and content of preventive health...

...epressed, distraught were seldom questioned, study...s) -- Pointing to a disconnect between doctors and...ests that large numbers of physicians fail to spot...r a similar disorder. , Only 36 percent of the doc...

... Today, Speaker of the,House Nancy Pelosi (D-CA) a...d Louise Slaughter (D-NY), introduced the Coordina...7. This legislation would establish a,national pub...ards, and increase funding for locally-based pilot...

Other Medicine News:Health News:Rulings Send Lawsuits Against State Farm, American Family Back to Court, Hagens Berman Sobol Shapiro Announces 2 Health News:Rulings Send Lawsuits Against State Farm, American Family Back to Court, Hagens Berman Sobol Shapiro Announces 3 Health News:US FDA Fast Tracks PI-88 for the Treatment of Post Resection Liver Cancer 2 Health News:US FDA Fast Tracks PI-88 for the Treatment of Post Resection Liver Cancer 3 Health News:Benjamin England, Former FDA Regulatory Counsel, to Testify on FDA Import Strategic Plan Before House Appropriations Subcommittee 2 Health News:New study likely to fuel debate over annual physical exams 2 Health News:New study likely to fuel debate over annual physical exams 3 Health News:Doctors Often Fail to Spot Suicidal Patients 2 Health News:Doctors Often Fail to Spot Suicidal Patients 3 Health News:Pelosi, Slaughter and Tubbs Jones Introduce Health Tracking Legislation 2

Rulings Send Lawsuits Against State Farm, American Family Back to Court, Hagens Berman Sobol Shapiro Announces US FDA Fast Tracks PI-88 for the Treatment of Post Resection Liver Cancer Benjamin England, Former FDA Regulatory Counsel, to Testify on FDA Import Strategic Plan Before House Appropriations Subcommittee New study likely to fuel debate over annual physical exams Doctors Often Fail to Spot Suicidal Patients Pelosi, Slaughter and Tubbs Jones Introduce Health Tracking Legislation

(Date:12/3/2009)...DALE, Pa., Dec. 3 Radiology imagin...-record integration capabilities at the November 2... The Connect.PACS(TM) product, enabling the fir... is the latest release in the company,s newly bran...Photo: http://www.newscom.com/cgi-bin/prnh/20091...

(Date:12/3/2009)...RSHOLM, Denmark and SAN DIEGO, California, Decembe...lly Inhibits miR-122, a microRNA Important for,Hep...Reducing Hepatitis C,Virus in the Bloodstream in C... C Virus , - SPC3649 Demonstrates Efficac...ous Adverse Events in the Treated Animals - Signal...

(Date:12/3/2009)...ec. 3 In response to th...tion technologies in the evolving healthcare deliv...ter for Health Informatics (DCHI) to provide a cam...e an innovative interdisciplinary approach to educ...ians, nurses and healthcare administrators with an...

Breaking Medicine Technology:MEDRAD Demonstrates PACS Injection-Record Integration at RSNA 2009 2 MEDRAD Demonstrates PACS Injection-Record Integration at RSNA 2009 3 New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 2 New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 3 New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 4 New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 5 Duke Medicine to Train Healthcare Professionals in Health Informatics 2 Duke Medicine to Train Healthcare Professionals in Health Informatics 3 Par Pharmaceutical Receives Final Approval to Market Generic Ultram 28R 29 ER 6276 1 Par Pharmaceutical Receives Final Approval to Market Generic Ultram 28R 29 ER 6276 2 Lilly Surpasses United Way 2009 Campaign Goal 6272 1 Lilly Surpasses United Way 2009 Campaign Goal 6272 2 Lilly Surpasses United Way 2009 Campaign Goal 6272 3 Raleigh Day Spa Blue Water Spa Raffles Off 2410 000 in Day Spa Packages for Contributing to Raleigh Food Drive 61407 1 Raleigh Day Spa Blue Water Spa Raffles Off 2410 000 in Day Spa Packages for Contributing to Raleigh Food Drive 61407 2

[0] MEDRAD Demonstrates PACS Injection-Record Integration at RSNA 2009 [0] New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C [0] Duke Medicine to Train Healthcare Professionals in Health Informatics

...stic Systems, Inc. (OTC Bulletin Board: SSUR) toda...ent from Inverness Medical Innovations, Inc.,(Amex...ure and Inverness,signed two additional agreements...reby Inverness acquired an option to the exclusive...ertain infectious disease diagnostic,tests develop...

...ERN, Pa., Oct. 17 Cutanea Life Sciences, an,emerg...proving human health,and appearance through the de...diseased and aging skin conditions, today announce...al of Omiganan. The trial compared Omiganan 2.5% ...ulopustular rosacea. Study results demonstrated th...

Other Medicine Technology:StatSure Signs Strategic Financing and License Deals with Inverness Medical Innovations 2 StatSure Signs Strategic Financing and License Deals with Inverness Medical Innovations 3 Cutanea Announces Promising Phase II Results in Rosacea with Omiganan 2 Cutanea Announces Promising Phase II Results in Rosacea with Omiganan 3 Cutanea Announces Promising Phase II Results in Rosacea with Omiganan 4 Cutanea Announces Promising Phase II Results in Rosacea with Omiganan 5 Cutanea Announces Promising Phase II Results in Rosacea with Omiganan 6

StatSure Signs Strategic Financing and License Deals with Inverness Medical Innovations Cutanea Announces Promising Phase II Results in Rosacea with Omiganan

Buratto Insertion Forceps - Angled

Hydroview Insertion Forceps - Titanium

Hydro Insertion Forceps

Kellan Lens Inserter Forceps

Medicine Products:

Buratto Insertion Forceps - Angled Hydroview Insertion Forceps - Titanium Hydro Insertion Forceps Kellan Lens Inserter Forceps

Celator(R) Pharmaceuticals To Present at Biotech Sho...( PRINCETON N.J. Jan. 8 /- Celator Phar...),Health